Molecular Foundations: Ketamine and MDMA
200 CAD + tax

Format: Asynchronous, online
Instructors: Content was written in consultation with Dr. Joe Flanders, PhD, OPQ and Dr. Devon Christie, M.D., CCFP, IFMCP, RTC
Duration: 8 hours

This course will bring you on a journey through the effects elicited by ketamine and MDMA on the body and mind as it relates to psychedelic-assisted therapy. The content developed for this course is based on current literature and research and analyzed through the lens of trauma and violence-informed care and through commitments to social justice, equity, dignity, inclusion, cultural safety, and humility.

In the course, you will learn about the dose ranges, indications, contraindications, and concomitant medications of ketamine and MDMA. You will also learn about some fundamental pharmacology and neurobiology as it relates to the administration of ketamine and MDMA in psychedelic-assisted therapy.

Continuing Education (CE) accreditation will be available upon completion. This course can be completed at your own pace whenever it is most convenient for you, however the course must be completed within 1 year of your registration date. If the course is not completed after 1 year, you will not be eligible for a refund, and you will need to re-register.
PHRI

Explore the molecular foundations of ketamine and MDMA

This set of two courses is geared towards mental health professional and therapists who want to learn more about the molecular structure of ketamine and MDMA. In each course, you will learn about the dose ranges, indications, contraindications, and concomitant medications of each psychedelic medicine. You will also learn about some fundamental pharmacology and neurobiology as it relates to the administration of psychedelic medicines in psychedelic-assisted therapy.

Consider also registering for the Molecular Foundations of psilocybin course.

Learning Objectives

By the end of this workshop, participants will know more about how to:

  • Apply pharmacological knowledge of ketamine and MDMA to the facilitation or development of a psychedelic-assisted therapy protocol in a clinical setting.
  • Compare the wide range of effects, side effects, effects of long-term use, and abuse potential of ketamine and MDMA.
  • Apply cultural safety and humility to the administration of ketamine and MDMA as part of psychedelic-assisted therapy in order to avoid cultural appropriation and cultural harm.
  • Screen clients and determine if ketamine and MDMA would be best suited for a given client or clinical presentation.
PHRI

About Dr. Joe Flanders PhD

Dr. Joe Flanders is the Founder and Director of Mindspace Wellbeing and an Executive Clinical Advisor at Numinus Wellness. He is a licensed psychologist and an Assistant Professor (Professional) at McGill University. He has an active practice as a psychotherapist, psychedelic-assisted psychotherapist and mindfulness teacher. He is also the host of the Psychedelic Therapy Frontiers and appears frequently in the media as an expert in mental health, mindfulness, and psychedelics.




Joe Flanders

About Dr. Devon Christie MD, CCFP, IFMCP, RTC

Dr. Devon Christie MD is a clinical instructor with the UBC Department of Medicine and has a focused practice in chronic pain management. She is also a Registered Counsellor emphasizing Relational Somatic Therapy for trauma resolution, and a certified Mindfulness Based Stress Reduction teacher (UCSD). She is trained to deliver both MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy. She teaches for the California Institute of Integral Studies Certificate Program in Psychedelic Therapy and Research, the Integrative Psychiatry Institute Certificate Program in Psychedelic Assisted Therapy, and the ONCA Foundation Psychedelic Therapy program. She is a Principal Investigator and study therapist for a current Canadian MAPS PBC-sponsored 20-participant open-label clinical trial investigating MDMA-assisted psychotherapy for PTSD. Devon is the Medical and Therapeutic Services Director with Numinus Wellness Inc., and is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future.





Dr. Devon Christie

FAQs

  • Will a certificate of completion be offered to participants?
    • Yes - for 4 hours per course (ketamine, MDMA))
  • Are there any live sessions in these courses?
    • No - the Molecular Foundations courses are entirely asynchronous and can be completed to your own schedule.
  • Can I register even if I live outside of Canada
    • Yes - absolutely


    Refund Policy

    If you are unable to attend the course, please send an e-mail confirming your cancellation to training@numinus.com. A 10% administration fee will be charged for any cancellations, based on the total cost of the course, plus tax. If you have any questions, please reach out to our team and we would be happy to support you.



    Disclaimer

    The continuing professional development program in no way promotes, condones, or facilitates illegal activity, and is strictly for educational and harm reduction purposes only. Please be aware that certain psychedelic substances still remain illegal in many jurisdictions, including Canada. This program and the contents of this website do not constitute medical advice, and are not a substitute for professional medical advice and treatment.